Skip to main content

Table 1 Characteristics of the study population at the first measurement (baseline)

From: Pharmacological treatment of increased vascular risk and cognitive performance in middle-aged and old persons: six-year observational longitudinal study

 

All

Control

Treatmenta

P valueb

n (%)

1.934 (100)

1.678 (100)

256 (100)

N/A

Age (years), mean (SD)

51 (10)

50 (10)

58 (10)

< 0.001

Age groups, n (%)

   

< 0.001

 35 to 44 years

542 (28)

520 (31)

22 (9)

 

 45 to 54 years

713 (37)

641 (38)

72 (28)

 

 55 to 64 years

449 (23)

357 (21)

92 (36)

 

 65 to 74 years

190 (10)

133 (8)

57 (22)

 

  ≥ 75 years

40 (2)

27 (2)

13 (5)

 

Gender, n (%)

   

< 0.001

 Men

916 (47)

760 (45)

156 (61)

 

 Women

1018 (53)

918 (55)

100 (39)

 

Educational level, n (%)

   

< 0.001

 Low (≤12 years)

624 (32)

498 (30)

126 (49)

 

 High (≥13 years)

1310 (68)

1180 (70)

130 (51)

 

Race, n (%)

 Western-European

1849 (96)

1604 (96)

245 (96)

0.62

 Other

72 (4)

61 (4)

11 (4)

 

Cardiovascular historyc, n (%)

19 (1)

4 (< 1)

15 (6)

< 0.001

Treatable vascular risk (points)d, mean (SD)

1 (3)

1 (3)

4 (3)

< 0.001

Cognitive performance

 RFFT (points), mean (SD)

74 (26)

76 (25)

64 (25)

< 0.001

 VAT (points), mean (SD)

10 (2)

10 (2)

9 (2)

< 0.001

 Composite z-scoree, mean (SD)

0.03 (0.78)

0.08 (0.77)

−0.30 (0.80)

< 0.001

  1. Abbreviations: RFFT Ruff Figural Fluency Test, VAT Visual Association Test, SD Standard deviation, N/A Not applicable
  2. a Treatment group included persons who had treatment of vascular risk factors for the first time at the first measurement of cognitive function
  3. bP values refer to comparisons between persons with and without treatment of vascular risk factors
  4. c All nineteen persons with a cardiovascular history had a cardiac event. There were no cerebrovascular of peripheral vascular event
  5. d Treatable vascular risk is based on the components of Framingham Risk Score for Cardiovascular Disease that are amenable to treatment and included diabetes mellitus, current smoker status, total cholesterol, HDL-cholesterol, systolic blood pressure and use of blood pressure lowering medication [24]
  6. e Cognitive performance was measured as a composite score of two tests (z-score): the Ruff Figural Fluency Test (RFFT) and the Visual Association Test (VAT) [20, 22]